XSHG
603233
Market cap3.12bUSD
Oct 09, Last price
18.76CNY
1D
2.18%
1Q
6.29%
IPO
29.14%
Name
DaShenLin Pharmaceutical Group Co Ltd
Chart & performance
P/E
17.30
P/S
0.78
EPS
1.08
Div yield, %
3.54%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
13.53%
Revenues
27.50b
+3.80%
Net income
1.24b
+35.04%
CFO
5.35b
+72.24%
Dividend
Jun 26, 20260.49 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1999, DaShenLin Pharmaceutical Group Co., Ltd. is a Chinese company based in Guangzhou. It operates across the pharmaceutical supply chain, engaging in the production, distribution, and direct sale of medicinal products throughout the country.
Key people
Changcheng Chen
Deputy General Manager, General Manager - Center · since 2023
Hong Chen
Deputy General Manager · since 2019
Xin Jiang
Deputy General Manager · since 2023
Tuoji Ke
Deputy General Manager, General Manager - Shenzhen Operations Region · since 2023
Qunfei Tan
Deputy General Manager, Director · since 2024
Guangzhi Peng
Chief Financial Officer, Secretary of the Board · since 2024
Yunfeng Ke
Chairman of the Board · since 2016
Guoqiang Ke
General Manager, Director · since 2024
Jie Li
Director · since 2019
Independent Director · since 2023
Liping Lu
Independent Director · since 2019
Zuyao Su
Independent Director · since 2019
Headquarters & legal address
广东省广州市荔湾区龙溪大道410号、410-1号
广州市, GD 510000
CN
广州市, GD 510000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||